Save your place

Sign in to WhoBought

Please try again later.

Nuvectis Pharma, Inc. (NVCT) institutional ownership

Latest close $19.08 Jul 21, 2026
Market cap$153M 52-week range SectorHealthcare
Funds holding · Q1 2026
44
reported NVCT position changes
Top owners · Q1 2026
No disclosed owners are available.
Institutional activity · Q1 2026
Activity unavailable N/A
34 buyers · 10 sellers

Nuvectis Pharma, Inc. (NVCT) price and institutional activity

Dates

Q1 2026

$0 bought by 34 investors
Citadel Advisors LLCIridian Asset Management LLC +32 more
$0 sold by 10 investors
Susquehanna International Group, LLPBarclays PLC +8 more
Bought Sold Totals per quarter; hover a bar for the names.

Nuvectis Pharma, Inc. (NVCT) institutional activity · 44

Investor Type Est. change Change Δ Own Date
Citadel Advisors LLC New· Q1 2026 +78K Q1 2026
Iridian Asset Management LLC · Added
Change +65K Date Q1 2026
Iridian Asset Management LLC Added· Q1 2026 +65K Q1 2026
UBS Group AG · Added
Change +30K Date Q1 2026
UBS Group AG Added· Q1 2026 +30K Q1 2026
Marshall Wace, LLP · New
Change +29K Date Q1 2026
Marshall Wace, LLP New· Q1 2026 +29K Q1 2026
Susquehanna International Group, LLP · Reduced
Change −29K Date Q1 2026
Susquehanna International Group, LLP Reduced· Q1 2026 −29K Q1 2026
Occam Crest Management LP · Added
Change +27K Date Q1 2026
Occam Crest Management LP Added· Q1 2026 +27K Q1 2026
Vanguard · Added
Change +27K Date Q1 2026
Vanguard Added· Q1 2026 +27K Q1 2026
Barclays PLC · Reduced
Change −21K Date Q1 2026
Barclays PLC Reduced· Q1 2026 −21K Q1 2026
Geode · Added
Change +20K Date Q1 2026
Geode Added· Q1 2026 +20K Q1 2026
BlackRock · Reduced
Change −18K Date Q1 2026
BlackRock Reduced· Q1 2026 −18K Q1 2026
Martingale Asset Management L P · New
Change +18K Date Q1 2026
Martingale Asset Management L P New· Q1 2026 +18K Q1 2026
Goldman Sachs Group Inc · Added
Change +15K Date Q1 2026
Goldman Sachs Group Inc Added· Q1 2026 +15K Q1 2026
T. Rowe Price Associates · New
Change +12K Date Q1 2026
T. Rowe Price Associates New· Q1 2026 +12K Q1 2026
State Street · Added
Change +12K Date Q1 2026
State Street Added· Q1 2026 +12K Q1 2026
Wells Fargo & Company · Reduced
Change −11K Date Q1 2026
Wells Fargo & Company Reduced· Q1 2026 −11K Q1 2026
Data through Q1 2026 · filed May 21, 2026
15 of 44

Famous investor activity in Nuvectis Pharma, Inc. (NVCT)

Nuvectis Pharma, Inc. (NVCT) insider trading

Company insiders, action and economics first; trade and filed dates last.
Dates
Insider Title Type Price Qty Value Owned ΔOwn Trade date Filed date
Mosseri Marlio Charles · 10% Owner Buy +$916K
Price $18.32 Qty +50K Owned 3.2M ΔOwn +1.6% Trade date Jun 30, 2026 Filed date Jul 1, 2026
Mosseri Marlio Charles 10% Owner Buy $18.32 +50K +$916K 3.2M +1.6% Jun 30, 2026 Jul 1, 2026
Bentsur Ron · Director Buy +$250K
Price $20.00 Qty +12K Owned 3.7M ΔOwn +0.3% Trade date Jun 30, 2026 Filed date Jul 1, 2026
Bentsur Ron Director Buy $20.00 +12K +$250K 3.7M +0.3% Jun 30, 2026 Jul 1, 2026
Hoberman Kenneth · Director Grant (A) 35K
Owned 168K Trade date Jun 11, 2026 Filed date Jun 12, 2026
Hoberman Kenneth Director Grant (A) 35K 168K Jun 11, 2026 Jun 12, 2026
Oliviero James F. III · Director Grant (A) 35K
Owned 123K Trade date Jun 11, 2026 Filed date Jun 12, 2026
Oliviero James F. III Director Grant (A) 35K 123K Jun 11, 2026 Jun 12, 2026
Sanchez Juan · Director Grant (A) 35K
Owned 113K Trade date Jun 11, 2026 Filed date Jun 12, 2026
Sanchez Juan Director Grant (A) 35K 113K Jun 11, 2026 Jun 12, 2026
Kaplan Matthew L. · Director Grant (A) 35K
Owned 160K Trade date Jun 11, 2026 Filed date Jun 12, 2026
Kaplan Matthew L. Director Grant (A) 35K 160K Jun 11, 2026 Jun 12, 2026
Shemesh Shay · Officer Grant (A) 150K
Owned 1.8M Trade date Jan 6, 2026 Filed date Jan 9, 2026
Shemesh Shay Officer Grant (A) 150K 1.8M Jan 6, 2026 Jan 9, 2026
Bentsur Ron · Director, Officer, 10% Owner Grant (A) 150K
Owned 3.7M Trade date Jan 6, 2026 Filed date Jan 9, 2026
Bentsur Ron Director, Officer, 10% Owner Grant (A) 150K 3.7M Jan 6, 2026 Jan 9, 2026
Poradosu Enrique · Officer Grant (A) 150K
Owned 1.8M Trade date Jan 6, 2026 Filed date Jan 9, 2026
Poradosu Enrique Officer Grant (A) 150K 1.8M Jan 6, 2026 Jan 9, 2026
Carson Michael J. · Officer Grant (A) 61K
Owned 200K Trade date Jan 6, 2026 Filed date Jan 9, 2026
Carson Michael J. Officer Grant (A) 61K 200K Jan 6, 2026 Jan 9, 2026
Bentsur Ron · Director, Officer, 10% Owner Buy +$29K
Price $5.72 Qty +5K Owned 3.5M Trade date Nov 5, 2025 Filed date Nov 6, 2025
Bentsur Ron Director, Officer, 10% Owner Buy $5.72 +5K +$29K 3.5M Nov 5, 2025 Nov 6, 2025
Sanchez Juan · Director Buy +$75K
Price $5.79 Qty +13K Owned 78K Trade date Nov 5, 2025 Filed date Nov 6, 2025
Sanchez Juan Director Buy $5.79 +13K +$75K 78K Nov 5, 2025 Nov 6, 2025
Kaplan Matthew L. · Director Buy +$64K
Price $5.84 Qty +11K Owned 125K Trade date Nov 5, 2025 Filed date Nov 6, 2025
Kaplan Matthew L. Director Buy $5.84 +11K +$64K 125K Nov 5, 2025 Nov 6, 2025
Mosseri Marlio Charles · 10% Owner Buy +$457K
Price $6.28 Qty +73K Owned 3.1M Trade date Oct 27, 2025 Filed date Oct 29, 2025
Mosseri Marlio Charles 10% Owner Buy $6.28 +73K +$457K 3.1M Oct 27, 2025 Oct 29, 2025
Mosseri Marlio Charles · 10% Owner Buy +$215K
Price $6.15 Qty +35K Owned 3.1M Trade date Oct 24, 2025 Filed date Oct 29, 2025
Mosseri Marlio Charles 10% Owner Buy $6.15 +35K +$215K 3.1M Oct 24, 2025 Oct 29, 2025
15 of 17
15 of 17 Sign in to continue to older insider transactions.

Nuvectis Pharma, Inc. (NVCT) activist and large shareholders

Dates
Owner/Filer identity Shares reported % of shares outstanding Filing date
Poradosu Enrique 1.2M
% of shares outstanding 8.3% Filing date Feb 13, 2023
Poradosu Enrique 1.2M 8.3% Feb 13, 2023
Shemesh Shay 1.2M
% of shares outstanding 8.2% Filing date Feb 13, 2023
Shemesh Shay 1.2M 8.2% Feb 13, 2023
Pontifax Management 4 G.p. (2015) Ltd. 2.9M
% of shares outstanding 1.5% Filing date Nov 5, 2024
Pontifax Management 4 G.p. (2015) Ltd. 2.9M 1.5% Nov 5, 2024
3 of 3

Nuvectis Pharma, Inc. (NVCT) ownership FAQ

Who owns NVCT?

44 reporting institutions disclosed NVCT position changes in the Q1 2026 snapshot.

How is institutional activity calculated?

For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.

What are activist and large shareholder filings?

An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.

Where does this data come from?

Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.

Why are ownership reports delayed?

Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.

How are missing table values shown?

A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.